Core Insights - Chengdu Heerkang Medical Technology Co., Ltd. has completed its Series A financing round, raising tens of millions of RMB, with investors including Huige Capital, Guosheng Capital, and Chengdu Gaotou Group [1][2]. Company Overview - Chengdu Heerkang Medical Technology Co., Ltd. focuses on software platform development in the chronic disease sector, positioning itself as a pioneer in the domestic auxiliary diagnosis and treatment field for chronic diseases [2]. Investment Details - The Series A financing was announced on November 3, 2025, with participation from Huige Capital and Guosheng Capital, while Chengdu Gaotou Group also took part in the investment [2]. - Prior to this, Huige Capital also participated in an undisclosed amount of angel round financing on October 27, 2024 [2]. Product Development - The company has developed proprietary artificial intelligence systems for diabetes management (DMS) and hypertension management (HMS), enhancing its capabilities in chronic disease management [2].
【投融资动态】合尔康A轮融资，融资额数千万人民币，投资方为怀格资本、国生资本等
Sou Hu Cai Jing·2025-11-05 11:32